Menu

Self-Experimentation Led to the Discovery of IgE

In the 1960s, immunologists took matters into their own hands—and under their own skin—to characterize an immunoglobulin involved in allergies.

Jun 1, 2017
Andrea Anderson

IN PURSUIT OF IgE: University of Uppsala researchers Gunnar Johansson and Hans Bennich characterized a protein from a myeloma patient using electrophoresis (drawings to the right reflect results in corresponding gels). The duo saw massive amounts of immunoglobulin (a) in the patient’s serum (ND), eclipsing that in normal serum (NS). Antibodies raised against the ND protein produced markedly similar patterns (b), suggesting ND was an immunoglobulin—a notion supported by removing ND light chains before running the gel (c). The remaining heavy chains belonged to IgE.
See full image: PDF
Reprinted from S.G.O. Johansson, H. Bennich, “Immunological studies of an atypical (myeloma) immunoglobulin,” Immunology, 13:381-94, 1967 with permission from Wiley

In the early 1960s, Kimishige Ishizaka, then an immunologist at the Children’s Asthma Research Institute and Hospital in Denver, volunteered himself as a human pincushion. In pursuit of understanding what was then a mysterious protein called reagin, Ishizaka had colleagues inject solutions of the protein into his own back. His self-torture—and that of peers around the globe who would likewise offer up their own skin for experiments—would ultimately lead to the discovery of immunoglobulin E (IgE), an antibody responsible for allergic reactions.

Researchers had been collecting clues about reagin—a molecule implicated in hay fever, allergic asthma, and other allergic conditions—decades before Ishizaka’s self-experimentation. Inspired by a 1919 report of a new horse allergy in a patient who received blood from a horse-sensitive donor, German researcher Carl Prausnitz injected serum from a fish-allergic colleague, Heinz Küstner, into his own arm in 1921.

The following day, Prausnitz pumped fish extract into the same site and the allergy emerged, a bright-red rash on his arm. With that, Prausnitz launched the Prausnitz-Küstner (P-K) test, one of several key tools ultimately used to discover IgE.

But before IgE was recognized, Ishizaka, with his wife and collaborator Teruko Ishizaka and colleague Margaret Hornbrook, took a detour. In 1963, they reported that reagin was a new form of immunoglobulin A (IgA). Soon after, they had doubts. For one thing, researchers had trouble reproducing the results. The University of Birmingham’s Dennis Stanworth later wrote that he also “hotly contested” the idea that reagin was IgA when the Ishizakas visited his lab in the 1960s—a move he believes “encouraged them to look again at this question.”

In 1966, the Ishizakas and Hornbrook used the P-K test to show persistent ragweed sensitivity in serum from affected individuals, even after adding antibodies to slurp up IgA (J Immunol, 97:75-85). The rash could be avoided by tossing in antibodies raised against reagin in rabbits, though, as the experiment on Ishizaka’s back had revealed.

Producing antibodies to reagin “was actually the key,” suggests Toshiaki Kawakami, an immunology researcher at the La Jolla Institute for Allergy and Immunology, where Kimishige Ishizaka was the founding scientific director and former president. “Using that antibody, they could identify that the factor was a new molecule because of the size and because of the activity,” says Kawakami.

The Ishizakas were not alone in their pursuit of reagin. At the University of Uppsala in Sweden, Gunnar Johansson and Hans Bennich were intently unraveling crucial physical and chemical properties of IgND, a protein found at sky-high levels in blood from an individual (initials N.D.) with an unusual form of myeloma. The duo, along with Stanworth and John Humphrey in the U.K., went on to show (in Humphrey’s skin) that, when delivered first, IgND blocked reagin’s activity, presumably because IgND was already interacting with reagin’s targets (The Lancet, 290:330-32, 1967).

Suspecting they were working on the same molecule, the Johansson- and Ishizaka-led teams swapped reagents and confirmed reagin and IgND were the same protein and a new form of immunoglobulin. In 1968 they agreed upon naming it IgE (Immunology, 15:323-24). 

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.